Literature DB >> 10528424

[The antiphospholipid syndrome during chronic lymphatic leukemia. An association with anti-factor VIII antibodies].

A Ghirarduzzi1, M Silingardi, M D'Incà, E Tincani.   

Abstract

Activated partial thromboplastin time may be prolonged as the result of either of two different autoimmune complications of chronic lymphocytic leukemia: the development of antiphospholipid antibodies, such as lupus anticoagulant or anticardiolipin antibodies, or anti-factor VIII inhibitors, such as acquired hemophilia A. In the rare simultaneous occurrence of both inhibitors, differential diagnosis of a prolonged activated partial thromboplastin time poses a number of problems during laboratory work-up, due to mutual interference of the commonly performed tests. Only careful clinical follow-up can disclose the significance of the laboratory findings. We report the case of concurrent antiphospholipid antibodies (lupus anticoagulant positivity, anticardiolipin antibodies; IgM 3880 MPL/mL and IgG 265 GPL/mL) and anti-factor VIII antibodies (46.8 Bethesda Units) in a patient with chronic B-cell lymphocytic leukemia who had prolonged activated partial thromboplastin time (78.8 s). The relationship between lymphoproliferative and antiphospholipid syndrome, laboratory work-up in the case of the association of antiphospholipid and anti-factor VIII antibodies, and related problems that occur during clinical management of the patient are also discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528424

Source DB:  PubMed          Journal:  Ann Ital Med Int        ISSN: 0393-9340


  2 in total

Review 1.  Lethal limb ischaemia in leukaemia. Case report and review of the literature.

Authors:  Cristina Belizna; Marc Antoine Pistorius; Bernard Planchon
Journal:  J Thromb Thrombolysis       Date:  2008-10-11       Impact factor: 2.300

2.  Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient.

Authors:  Jeremy W Jacobs; Savanah D Gisriel; Krishna Iyer; Henry M Rinder
Journal:  J Thromb Thrombolysis       Date:  2021-10-25       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.